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1. Introduction 
The nerve axon innervating mammalian skeletal 
muscle delivers trophic substances via axonal trans- 
port [l--3], in addition to electrical impulses which 
control the release of neurotransmitter [4]_ 
Denervation of skeletal muscle causes marked 
structural and physiological changes of the affected 
muscle including the sarcoplasmic reticulum (SR) 
which is believed to play an important role in regu- 
lating the intracellular [Ca”] [5,6]. Accumulation of 
Ca2+ by vesicles of fragmented sarcoplasmic reticulum 
(FSR) increases after a relatively short period of 
denervation [7-lo]. Ca2+-uptake by FSR vesicles 
from slow and fast muscle fibres also changes upon 
changing the innervation to the muscle flI,12]. Thus, 
it seems that the SR is under some form of neuro- 
trophic control. 
Certain neurotoxins have become important tools 
in studying neural trophic regulation [ 131. Among 
these are batrachotoxin @TX) and tetrodotoxin 
(TTX). BTX, when applied to a nerve, blocks axonal 
transport as well as impulse transmission whereas 
TTX only blocks impulse transmission and has no 
effect on axonal transport [14-l 71. Therefore, fol- 
lowing application of either BTX or TTX to a nerve 
the importance of axonal transport in exerting a 
neurotrophic control on muscle can be determined. 
Here we present evidence supporting the concept that 
Abbreviations.’ EGTA, [Ethylene+& (oxyethlenenkilo)) 
tetraacetic acid; FCCP, ~rbonylcyanide p-tr~uoromethoxy- 
pheny~ydrazone; POPOP, p-bis (2-(5-phenyloxazole)l- 
benzene; PPO, 2,5diphenyloxazole 
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axonal transport of neurotrophic factors plays a role 
in the regulation of Ca2+-uptake by muscle SR. 
2. Materials and methods 
2.1. Animals 
Adult female Sprague-Dawley rats (200-250 g) 
were used. One ~1 of BTX (lO_” mol) or TTX (lo+ 
mol) in 0.9% NaCl-10% dextrose was injected with a 
fine glass micropipette into the subperineural space of 
the peroneal nerve -15 mm before the nerve enters 
the muscle [ 161. The contralateral side was injected 
with the same volume of vehicle and was used as the 
experimental control. At various time intervals, the 
animals were sacrificed and the extensor digitorum 
longus (EDL) muscles removed. In each experiment 
FSR was prepared from a pool of 8-14 muscles. 
2.2. Chemicals 
TTX was purchased from Calbiochem-~hrjng Co., 
BTX was a gift from Drs E. X. Albuquerque and J. W. 
Daly, 45CaC12 was obtained from New England 
Nuclear and FCCP from Sigma Co. Other chemicals 
used were of reagent grade except POPOP and PPO 
which were of scintillation grade. Water used in all 
experiments was nanopure (NA~Opure, Barnstead) 
and the equipment was rinsed with 1 mM EGTA 
before use. 
2.3. Method 
The microsomal fraction containing the FSR 
vesicles was isolated from the tissue homogenate by 
ultracentrifugation as in [ 18 J, and was used for Ca2+- 
uptake on the same day of preparation. Ca2+-uptake 
by the FSR vesicles in the absence and presence of 
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oxalate was determined by the millipore filtration 
method [19]. To inhibit mitochondrial Ca2+ uptake, 
FCCP was also included in the reaction mixture [20]. 
The Ca’+ concentrating ability and passive efflux of 
Ca” from the FSR vesicles was measured as in [21]. 
Protein was determined according to [22] and radio- 
activity was measured by liquid scintillation in a 
toluene base cocktail containing Triton X-I 14 and 
POPOP-PPO [ 231. 
3. Results 
The muscle wet weight and yield of FSR showed a 
progressive loss up to 12 days after application of 
BTX to the innervating nerve. However, the muscle 
weight recovered partially at longer time periods. A 
similar decrease in muscle weight and yield of FSR 
has been observed in denervated EDL 19,101. In con- 
trast, when the nerve was poisoned with TTX there 
was no marked decrease in muscle weight (table 1). 
Ca*+ uptake in the absence of oxalate by FSR 
vesicles isolated from muscles innervated by BTX- 
treated nerves decreased gradually, reaching 59% of 
control at -12 days (table 2). At subsequent time 
intervals there was a partial recovery in the Ca”- 
uptake capacity. However, at 24 days it was still 29% 
below control values. The uptake of Ca*+ by FSR 
from 4-day denervated muscle shows a similar trend 
by being 20% lower than that obtained from the con- 
tralateral control side. In contrast, FSR isolated from 
muscles in which TTX was applied to the nerve 
showed only a small (10%) decrease in their ability to 
accumulate Ca*+ in the absence of oxalate. Ca2+ uptake 
in the presence of oxalate, which has been termed 
‘calcium loading’ [24] and is believed to simulate the 
in vivo sequestering of Ca2+ by the SR during muscle 
relaxation, was also examined. As shown in table 2 
the Ca*‘-loading by FSR from muscles innervated by 
BTX-treated nerves showed an increase during the 
first 12 days after application of the toxin to the 
nerve. A similar increase in Ca*+-loading has been 
obtained in FSR from denervated muscle ([7-lo], 
table 2). In sharp contrast, following TTX applica- 
tion to the nerve the FSR did not show a comparable 
increase in Ca2’-loading. 
The total Ca*‘-loading capacity of FSR does not 
necessarily bear any relationship to the function of 
the FSR, the latter being to reduce the intracellular 
[Ca”‘] to -10e7 M [21]. A measure of the Ca2+-con- 
centrating ability of the FSR at sub-saturating [Ca’+] 
would supply kinetic characteristics of the Ca*‘-uptake 
process equivalent to that seen in vivo. Using this 
approach we found that the Ca”-concentrating abil- 
ity of FSR from EDL in which the nerve had been 
exposed to BTX 12 days in advance was lower than 
that of the contralateral control preparation (fig.1 a). 
In addition to showing a decreased Ca*‘-uptake the 
passive efflux of Ca*+ was greater in the BTX treated 
preparations (fig.lb). 
Table 1 
Muscle wet weight after exposing the innervating nerve to BTX, TTX or denervation 
Days 
after 
treat- 
ment 
Muscle (EDL) wet weight (mg) 
Contra- 
BTX 
% Contra- 
TTX 
% Contra- Denerva- % 
lateral change lateral change lateral tion change 
4 115.5 (2) 104.2 (2) - 9.8 142.9 (2) 136.7 (2) -4.0 112.0 (1) 115 (1) + 2.0 
8 165.7 (3) 139.3 (3) -15.9 117.8 (3) 113.9 (3) -3.3 191.7 (1) 141.7 (1) -26.1 
+17sa +17.8a I 8.2a + 4.2a 
12 134.8 (5) 95.64 (5) -29.0 
+ 2.87a t 5.29a 
_ 
16 108.4 (2) 88.2 (2) -18.6 _ _ 
24 130.8 (1) 121.7 (1) - 7.0 _ _ 
a Mean f SEM 
The peroneal nerve innervating one extensor received toxin (BTX or TTX) while the contralateral received vehicle and served as 
control. Numbers in parenthesis indicate the number of experiments performed. In each experiment, 8-12 pairs of muscle (EDL) 
were removed and the average wet weight per muscle determined 
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Fig.1. Calcium uptake and efflux from FSR 12 days following 
neural application of BTX. Assay procedure was that in j2l], 
in Tris-maleate (pH 6.8) 20 mM; KC1 0.1 M; MgCl, 5 mM; 
45CaC1, 10 IIM (1000 dpm~nmol); ATP 1.16 mM; FCCP 
2 &g/ml; potassium oxalate 5 mM and FSR protein 0.1 mg/ml. 
4. Discussion 
Experimental evidence has accumulated showing 
neurogenic control of many biochemical properties 
of muscle. Thus denervation or cross-innervation of a 
slow or fast muscle by a fast or slow motor nerve, 
respectively, leads to changes in the Ca”-transporting 
activity of the FSR; EGTA-sensitive Ca-Mg, K- 
ATPase; lactic dehydrogenase isoenzyme pattern and 
the molecular properties of myosin [3,6,11.12]. The 
neurogenic basis for these changes is not clear and 
could reside in the frequency of muscle contraction 
which is under neural control or alternatively in 
trophic factors supplied to the muscle by axonal 
transport [ 1,3]. By exploiting the selective action of 
neurotoxins such as TTX and BTX on impulse con- 
duction and axonal transport we have obtained evi- 
dence that ~a”-mobilisation by FSR is under trophic 
control by neural factors supplied to the muscle by 
axonal transport. 
BTX induces a state of denervation in muscle by 
blocking both axonal transport and impulse conduc- 
tion. This is seen in the parallel weight loss observed 
in denervated muscle [9,10] and that obtained from 
BTX-treated nerves. In addition, following denerva- 
tion there is an increase in total Ca2’-loading by FSR 
in the presence of oxalate [7-lo]. This is also 
observed in muscle innervated by BTX-poisoned 
nerves. While Ca”-uptake in the presence of oxalate 
increased in both denervated and BTX-treated prepa- 
rations, a decrease in Ca”-uptake by FSR from both 
preparations was observed in the absence of oxalate 
([lo] table 2). In denervated muscle an increase in 
Ca2+-release from Ca’*-loaded FSR has been reported 
[lo]. A similar increase in Cazf-release was observed 
in FSR preparations obtained from muscle innervated 
by a BTX-poisoned nerve (fig. 1 b). In marked con- 
trast TTX, which only blocks impulse conduction, 
had minimal effects on Ca2’-mobilization by FSR. 
The decrease in Ca”-uptake by FSR from muscle 
innervated by a BTX-poisoned nerve can be explained 
by assuming the formation of larger vesicles similar 
to that reported for denervated and dystrophic mus- 
cle which have a decreased Ca”-influx rate [10,21]. 
Alternatively the leakiness of the FSR could be due 
to changes in the organization of the membrane sim- 
ilar to that observed f.o~Iowing exposure to ether 
which leads to increased leakiness of the FSR 1251, 
This is further supported by the observation that the 
protein electrophoretic pattern of the FSR does not 
change following neural application of BTX; there is. 
however, an increase in the FSR lipid content (unpub- 
lished). 
A direct effect of BTX on muscle due to diffusion 
of the toxin has been ruled out on the basis of muscle 
membrane potential measurements and the lateral 
spread in the nerve of [3H]BTX which is restricted to 
an area of 4-6 mm from the injection site [ 161. In 
addition, when BTX (10-‘2 mol) was added to the 
Ca2’-uptake incubation media no change in the 
amount of Ca”’ accumulated was observed. 
In summary, by selectively blocking axonal trans- 
port and/or impulse conduction in nerves innervating 
fast skeletal muscle we have demonstrated that axonal 
transport plays a role in the control of the Ca’+-trans- 
port system. 
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